Table 2.
Clinical outcomes for NEW Tx Group 2
| Pre-treatment Mean (± SD) | Post-treatment Mean (± SD) | t | p | Effect size (r) | |
|---|---|---|---|---|---|
| Weight (lbs) | 191.3 (± 33.7) | 182.3 (± 32.7) | 3.61 | 0.015a | 0.13 |
| Waist (cm) | 40.3 (± 7.3) | 38.6 (± 6.7) | 3.80 | 0.013a | 0.12 |
| Weekly exercise (min)* | 233.8 (± 65.0) | 333.1 (± 167.1) | −1.46 | 0.204 | 0.36 |
| CGI-BP | 3.5 (± 1.4) | 2.7 (± 1.0) | 1.75 | 0.141 | 0.32 |
| MADRS | 20.3 (± 11.1) | 11.5 (± 7.3) | 4.05 | 0.010a | 0.42 |
| YMRS | 13.2 (± 11.3) | 7.3 (± 7.2) | 1.03 | 0.349 | 0.29 |
| LIFE-RIFT† | 11.8 (± 3.4) | 9.3 (± 2.6) | 3.73 | 0.014a | 0.38 |
| Quality of Life† | 51.5 (± 19.3) | 68.8 (± 21.7) | −2.47 | 0.056a | 0.39 |
*
Weekly exercise (min) is the average weekly duration of exercise before versus after the completion of the exercise module of NEW Tx.
†
Improvement in quality of life over the study period is indicated by a decrease in total score on the LIFE-RIFT, but an increase on the Quality of Life scale.
a
All significant analyses remained significant when using a Wilcoxon matched pair non-parametric analysis.
SD: standard deviation; CGI-BP: Clinical Global Impression Scale-Bipolar Version; MADRS: Montgomery Asberg Depression Rating Scale; YMRS: Young Mania Rating Scale; LIFE-RIFT: Range of Impaired Functioning Tool